EGFR and head and neck squamous cell carcinoma: Anti-EGFR monoclonal antibodies (cetuximab and panitumumab) improve survival in metastatic CRC and HNSCC by blocking receptor–ligand interactions, preventing EGFR activation, and inducing ADCC [118,119,120].